FDA Grants Fast Track Designation for LYT-200 to Treat Head and Neck Cancers
Treatment with LYT-200 is currently being assessed in a phase 1/2 adaptive design trial in advanced/metastatic solid tumors and in a phase 1b clinical trial.
Aleksandra Filipovic Deric Sherman Abbvie Inc Puretech Health Memorial Sloan Kettering Cancer Center National Cancer Institute
Source: pharmacytimes.com